PatientsVille.com Logo

PatientsVille

Uralyt Side Effects

Common Uralyt Side Effects


The most commonly reported Uralyt side effects (click to view or check a box to report):

Intestinal Stenosis (2)
Melaena (2)
Renal Disorder (2)
Liver Disorder (2)
Hepatic Failure (1)
Vomiting (1)
Gamma-glutamyltransferase Increased (1)
Alanine Aminotransferase Increased (1)
Altered State Of Consciousness (1)
Toxicity To Various Agents (1)
Abdominal Pain (1)
Gait Disturbance (1)
Malignant Neoplasm Of Renal Pelvis (1)
Ileal Stenosis (1)
Hypertension (1)
Ileal Ulcer (1)
Interstitial Lung Disease (1)
Platelet Count Decreased (1)
Malaise (1)
Sepsis (1)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Uralyt Side Effects Reported to FDA

The following Uralyt reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Uralyt on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Melaena, Intestinal Stenosis
This is a report of a male patient (weight: NA) from JAPAN, suffering from the following symptoms/conditions: NA, who was treated with Uralyt (dosage: 9df, start time: Jan 01, 2003), combined with:
  • Vesicare (5 Mg)
  • Elaszym (7200 Mg)
  • Mobic
  • Urocalun (2025 Mg)
  • Calbock (16 Mg)
  • Mobic
  • Loxonin
  • Aricept (5 Mg)
and developed a serious reaction and side effect(s). The consumer presented with:
  • Melaena
  • Intestinal Stenosis
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Uralyt treatment in male patients, resulting in melaena side effect. The patient was hospitalized.

Cerebral Haemorrhage
This report suggests a potential Uralyt Cerebral Haemorrhage side effect(s) that can have serious consequences. A 63-year-old male patient (weight: NA) from JAPAN was diagnosed with the following symptoms/conditions: NA and used Uralyt (dosage: NA) starting Jul 04, 2011. Soon after starting Uralyt the patient began experiencing various side effects, including:
  • Cerebral Haemorrhage
Drugs used concurrently:
  • Rabeprazole Sodium
  • Ketoprofen
The patient was hospitalized and became disabled. Although Uralyt demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as cerebral haemorrhage, may still occur.

Gait Disturbance, Altered State Of Consciousness, Dizziness, Vomiting, Toxicity To Various Agents, Cognitive Disorder
This Gait Disturbance, Altered State Of Consciousness, Dizziness, Vomiting, Toxicity To Various Agents, Cognitive Disorder problem was reported by a physician from JAPAN. A 73-year-old male patient (weight: NA) was diagnosed with the following symptoms/conditions: NA. On Feb 23, 2011 this consumer started treatment with Uralyt (dosage: NA). The following drugs were being taken at the same time:
  • Atelec
  • Thiola (2000 Mg, Unk)
  • Avapro
  • Tegretol (4000mg, (5 Tablets 4 Times A Day))
When commencing Uralyt, the patient experienced the following unwanted symptoms/side effects:
  • Gait Disturbance
  • Altered State Of Consciousness
  • Dizziness
  • Vomiting
  • Toxicity To Various Agents
  • Cognitive Disorder
The patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as gait disturbance, may become evident only after a product is in use by the general population.

Condition Aggravated, Renal Disorder, Hypertension
This is a report of a male patient (weight: NA) from JAPAN. The patient developed the following symptoms/conditions: hyperuricaemia,hypercholesterolaemia and was treated with Uralyt (dosage: 3 G, Unk) starting Aug 24, 2004. Concurrently used drugs:
  • Zetia (10 Mg, Unk)
  • Tanatril
  • Lansoprazole (15 Mg, Unk)
  • Tekturna (150 Mg)
  • Urinorm (100 Mg, Unk)
  • Adalat (40 Mg, Unk)
  • Losartan Potassium (Unk)
  • Atelec (20 Mg, Unk)
Soon after that, the consumer experienced the following side effects:
  • Condition Aggravated
  • Renal Disorder
  • Hypertension
This opens a possibility that Uralyt treatment could cause the above reactions, including condition aggravated, and some male subjects may be more susceptible.


Intestinal Stenosis, Melaena
A male patient (weight: NA) from JAPAN with the following symptoms/conditions: NA started Uralyt treatment (dosage: 9df) on Jan 01, 2003. Soon after starting Uralyt treatment, the subject experienced various side effects, including:
  • Intestinal Stenosis
  • Melaena
Concurrently used drugs:
  • Calbock (16 Mg)
  • Isosorbide Dinitrate (80 Mg)
  • Isalon (900 Mg)
  • Mobic
  • Loxonin
  • Elaszym (7200 Mg)
  • Gastrozepin (225 Mg)
  • Mobic
The patient was hospitalized. This finding indicates that some male patients could be more vulnerable to Uralyt.

Malaise, Aspartate Aminotransferase Increased, Gamma-glutamyltransferase Increased, Alanine Aminotransferase Increased, Liver Disorder
A 43-year-old female patient from JAPAN (weight: NA) experienced symptoms, such as: NA and was treated with Uralyt (magnesium Prosphate, Solidago Virgaurea, Arnica Montana Extrac(dosage: NA). The treatment was initiated on May 14, 2011. After that a consumer reported the following side effect(s):
  • Malaise
  • Aspartate Aminotransferase Increased
  • Gamma-glutamyltransferase Increased
  • Alanine Aminotransferase Increased
  • Liver Disorder
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Uralyt (magnesium Prosphate, Solidago Virgaurea, Arnica Montana Extrac efficacy:
  • Prednisolone
  • Probenecid
  • Lansoprazole


Conjunctival Hyperaemia
In this report, Uralyt was administered for the following condition: NA.A male consumer from JAPAN (weight: NA) started Uralyt treatment (dosage: NA) on Jun 01, 2011.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Conjunctival Hyperaemia
A possible interaction with other drugs could have contributed to this reaction:
  • Famotidine (40 Mg)
  • Pradaxa (220 Mg)
  • Enalapril Maleate (2.5 Mg)
  • Eplerenone (25 Mg)
  • Lasix (20 Mg)
  • Urinorm (25 Mg)
  • Carvedilol (5 Mg)
  • Famotidine (10 Mg)
Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Uralyt treatment could be related to the listed above side effect(s).

Interstitial Lung Disease
This is a report of the following Uralyt side effect(s):
  • Interstitial Lung Disease
A 70-year-old male patient from JAPAN (weight: NA) presented with the following condition: hyperuricaemia,diabetes mellitus and received a treatment with Uralyt (dosage: NA) starting: May 16, 2008.The following concurrently used drugs could have generated interactions:
  • Januvia
  • Allopurinol
  • Lipitor
  • Allopurinol
  • Potassium Sodium Hydrogen Citrate
  • Actos
The patient was hospitalized.This report suggests that a Uralyt treatment could be associated with the listed above side effect(s).

Malignant Neoplasm Of Renal Pelvis
This Uralyt (sodium Citrate Acid, Potassium Citrate) report was submitted by a 66-year-old male consumer from JAPAN (weight: NA). The patient was diagnosed with: NA and Uralyt (sodium Citrate Acid, Potassium Citrate) was administered (dosage: NA) starting: Jan 20, 2009. The consumer developed a set of symptoms:
  • Malignant Neoplasm Of Renal Pelvis
Other drugs used simultaneously:
  • Crestor (rosumvastatin Calcium)
  • Metformin Hydrochloride
  • Actos (15 Mg (15 Mg,1 D) Per Oral)
  • Glucobay
  • Amaryl
Those unexpected symptoms could be linked to a Uralyt (sodium Citrate Acid, Potassium Citrate) treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Liver Disorder, Renal Disorder, Sepsis, Hepatic Failure
This is a report of a possible correlation between Uralyt use and the following symptoms/side effect(s):
  • Liver Disorder
  • Renal Disorder
  • Sepsis
  • Hepatic Failure
which could contribute to an assessment of Uralyt risk profile.A 63-year-old male consumer from JAPAN (weight: NA) was suffering from NA and was treated with Uralyt (dosage: Unk) starting Dec 01, 2010.Other concurrent medications:
  • Intron A (Unk)
  • Nexavar (200 Mg, Bid)
  • Allopurinol (Unk)
The patient was hospitalized.

Ileal Ulcer, Diarrhoea, Ileal Stenosis, Abdominal Pain
A 73-year-old male patient from JAPAN (weight: NA) presented with the following symptoms: NA and after a treatment with Uralyt (dosage: NA) experienced the following side effect(s):
  • Ileal Ulcer
  • Diarrhoea
  • Ileal Stenosis
  • Abdominal Pain
The treatment was started on NS. Uralyt was used in combination with the following drugs:
  • Zantac
  • Olmetec
  • Sigmart
  • Allopurinol
  • Omeprazole
  • Norvasc
  • Aspirin (Unk)
The patient was hospitalized.This report could alert potential Uralyt consumers.

Platelet Count Decreased, White Blood Cell Count Decreased
In this report, a male patient from JAPAN (weight: NA) was affected by a possible Uralyt side effect.The patient was diagnosed with hyperuricaemia,reflux oesophagitis,hypertension. After a treatment with Uralyt (dosage: NA, start date: Jun 04, 2008), the patient experienced the following side effect(s):
  • Platelet Count Decreased
  • White Blood Cell Count Decreased
The following simultaneously used drugs could have led to this reaction:
  • Omepral
  • Amlodin Od
  • Zyloric
The findings here stress that side effects should be taken into consideration when evaluating a Uralyt treatment.



Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Uralyt Side Effects

    Did You Have a Uralyt Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Uralyt for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Uralyt Safety Alerts, Active Ingredients, Usage Information

    NDC53145-311
    TypeHUMAN OTC DRUG
    Proprietary NameAuralyt
    NameCarbamide Peroxide
    Dosage FormLIQUID
    RouteTOPICAL
    On market since20140101
    LabelerMenper Distributors, Inc
    Active Ingredient(s)CARBAMIDE PEROXIDE
    Strength(s)7.8
    Unit(s)mg/12mL
    Pharma Class

    More About Uralyt

    Side Effects reported to FDA: 12

    Uralyt safety alerts: 2013

    Reported hospitalizations: 7

    Latest Uralyt clinical trials

    Uralyt Reviews

    No reviews, be a first to report a side effect via side effect reporting form